• Lenalidomide and Epigenetic Leverage in Myeloma

  2026-08-22

  Lenalidomide (CC-5013) is more than an immunomodulatory compound: emerging evidence shows that epigenetic reprogramming through DOT1L inhibition can intensify innate immune signaling and improve lenalidomide responsiveness in multiple myeloma models. This article translates that mechanism into practical experimental and strategic guidance.

• Low-Dose Chlorhexidine Against E. faecalis Biofilms

  2026-08-21

  A 2024 in vitro study shows that low chlorhexidine concentrations affect Enterococcus faecalis through convergent membrane, morphological, biofilm, and transcriptional changes rather than through a single antibacterial endpoint. The findings support mechanistically informed endodontic disinfection research while emphasizing the need for validation in multispecies biofilms, dentin models, and clinical settings.

• JC-1 for Mitochondrial Membrane Potential Assays

  2026-08-20

  JC-1 converts mitochondrial polarization into a practical red-to-green fluorescence ratio for live-cell studies. This article translates the DRP1-centered findings of a recent anaplastic thyroid carcinoma study into assay design, workflow controls, and troubleshooting strategies for apoptosis detection and mitochondrial dysfunction research.

• Alda 1 ALDH2 Activator Workflows for Cardiac Research

  2026-08-20

  Alda 1 provides a genotype-aware way to activate ALDH2, quantify aldehyde detoxification, and connect enzyme rescue with cardiomyocyte proliferation. This workflow-oriented guide covers cardiac ischemia research, pressure-overload models, assay design, and the limitations of extending the platform to radiation-induced dermatitis mitigation.

• HyperScribe™ T7 High Yield RNA Synthesis Kit Plus

  2026-08-19

  This scenario-driven guide explains how HyperScribe™ T7 High Yield RNA Synthesis Kit Plus, SKU K1401, can standardize RNA inputs for cell viability, proliferation, and cytotoxicity experiments. It connects practical transcription controls with preliminary evidence from FLCN mRNA rescue research while distinguishing documented product performance from assay-specific validation.

• iPSC Organoids Reveal Pan-Tissue HEV Infection

  2026-08-19

  This reference study establishes induced pluripotent stem cell-derived liver, intestinal and brain organoids as multilineage models that sustain complete life-cycle propagation of clinical hepatitis E virus genotypes 1, 3 and 4. The platform resolves tissue-specific tropism, injury and host-response phenotypes while providing a physiologically relevant system for antiviral evaluation.

• Pam3CSK4 Workflows for TLR1/2 Immune Studies

  2026-08-18

  Pam3CSK4 provides a controlled TLR1/2 agonist workflow for macrophage, platelet, allergy, and neuroimmune experiments. Its greatest value is as a defined inflammatory trigger that can be paired with neural stimulation to test, rather than assume, somato-autonomic regulation of immunity.

• TPCA-1: IKK-2 Inhibitor Workflow

  2026-08-18

  TPCA-1 is a selective IKK-2 inhibitor for separating NF-κB-driven cytokine signaling from RIPK1-regulated cell-death responses. This guide converts its biochemical profile into practical cell, cytokine, arthritis-model, and troubleshooting workflows.

• LRRC8A–Caveolin-1 Signaling in PDAC Growth

  2026-08-17

  The reference study identifies a cholesterol-dependent LRRC8A–Caveolin-1 complex that connects cell-volume regulation with KRAS/EGFR signaling, ribosome biogenesis, and proliferative expansion in pancreatic ductal adenocarcinoma. Its integrated genetic, pharmacological, xenograft, organoid, and proteomic evidence positions this membrane axis as a mechanistic vulnerability while suggesting practical readouts for biosynthetic growth.

• Cefazedone–Etimicin UPLC–MS/MS Pharmacokinetics

  2026-08-17

  Cui and colleagues developed and validated an ultra-fast LC–tandem MS assay for simultaneous measurement of cefazedone and etimicin in beagle dog plasma. The method enabled a pharmacokinetic comparison of combined versus single intravenous administration and found no obvious pharmacokinetic differences under the tested conditions.

• Mubritinib–HSA Recognition: Methods and Findings

  2026-08-16

  The reference study maps how Mubritinib (TAK 165) interacts with human serum albumin using fluorescence, biochemical, spectroscopic, and molecular docking approaches. Its findings identify moderate-affinity binding at albumin site I, static fluorescence quenching, subtle structural perturbation, and competitive inhibition of HSA esterase-like activity, providing a pharmacological context for interpreting the compound’s distribution and free fraction.

• Metoprolol Tartrate in β1 Research Workflows

  2026-08-15

  Metoprolol Tartrate is a selective β1-adrenergic blocking agent for separating cardiac β1 signaling from broader adrenergic effects. This workflow-focused guide covers concentration design, cardiomyocyte assays, comparative HCT experiments, and troubleshooting for reproducible cardiovascular research.

• Ziprasidone HCl: From Solubility to Signal

  2026-08-15

  Ziprasidone HCl connects receptor pharmacology, GOT1 inhibition, and formulation science in one research workflow. This article explains how solubility and exposure control can improve interpretation across neuroscience research and pancreatic cancer models.

• Alda 1: Practical ALDH2 Activation Workflows

  2026-08-14

  Alda 1 is an ALDH2 activator for connecting aldehyde detoxification assays with cardiac stress, cardiomyocyte proliferation, and radiation-injury models. This guide translates its reported activity against ALDH2*1 and ALDH2*2 into practical workflows, controls, and troubleshooting strategies for preclinical research.

• Pexmetinib (ARRY-614): Reliable Cell Assays

  2026-08-13

  Learn how Pexmetinib (ARRY-614), SKU B6012, can support more interpretable viability, proliferation, and cytokine-inhibition workflows. This scenario-based guide connects formulation, potency benchmarks, controls, and cross-domain limitations to practical laboratory decisions.

449 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page